RU2019133676A - Новые композиции и способы - Google Patents
Новые композиции и способы Download PDFInfo
- Publication number
- RU2019133676A RU2019133676A RU2019133676A RU2019133676A RU2019133676A RU 2019133676 A RU2019133676 A RU 2019133676A RU 2019133676 A RU2019133676 A RU 2019133676A RU 2019133676 A RU2019133676 A RU 2019133676A RU 2019133676 A RU2019133676 A RU 2019133676A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- composition
- composition according
- free base
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 33
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012458 free base Substances 0.000 claims 10
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 7
- 239000013078 crystal Substances 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 4
- -1 7H-pyrido [3 ', 4': 4,5] pyrrolo [1,2,3-de] quinoxalin-8-yl Chemical group 0.000 claims 4
- 239000007921 spray Substances 0.000 claims 4
- HOIIHACBCFLJET-SFTDATJTSA-N 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido-[3',4':4,5]-pyrrolo[1,2,3-de]quinoxalin-8-(7h)-yl)-1-(4-fluorophenyl)-1-butanone Chemical compound C([C@@H]1N2CCN(C=3C=CC=C(C2=3)[C@@H]1C1)C)CN1CCCC(=O)C1=CC=C(F)C=C1 HOIIHACBCFLJET-SFTDATJTSA-N 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229940002226 buccal film Drugs 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000002274 desiccant Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 229940041672 oral gel Drugs 0.000 claims 1
- 229940041678 oral spray Drugs 0.000 claims 1
- 239000000668 oral spray Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 239000006190 sub-lingual tablet Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940098466 sublingual tablet Drugs 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Claims (20)
1. Трансмукозальная фармацевтическая композиция, включающая 1-(4-фтор-фенил)-4-((6bR,10aS)-3-метил-2,3,6b,9,10,10a-гексагидро-1H,7H-пиридо[3′,4′:4,5]пирроло[1,2,3-de]хиноксалин-8-ил)-бутан-1-он (Соединение формулы I) в форме свободного основания, со-кристалла или соли, или включающая 1-(4-фтор-фенил)-4-((6bR,10aS)-2,2-d2-3-метил-2,3,6b,9,10,10a-гексагидро-1H,7H-пиридо[3′,4′:4,5]пирроло[1,2,3-de]хиноксалин-8-ил)-бутан-1-он (Соединение формулы II) в форме свободного основания, со-кристалла или соли, или включающая -(4-фтор-фенил)-4-((6bR,10aS)-1,1,2,2-d4-3-метил-2,3,6b,9,10,10a-гексагидро-1H,7H-пиридо[3′,4′:4,5]пирроло[1,2,3-de]хиноксалин-8-ил)-бутан-1-он (Соединение формулы III) в форме свободного основания, со-кристалла или соли.
2. Композиция по п. 1, где композиция включает соединение формулы I или соединение формулы II или соединение формулы III в форме свободного основания.
3. Композиция по п. 1, где композиция включает соединение формулы I или соединение формулы II или соединение формулы III в форме соли, например, в форме фармацевтически приемлемой соли.
4. Композиция по п. 3, где солевая форма представляет собой тозилат, например, в форме кристаллической соли.
5. Композиция по любому из предшествующих пунктов, где композиция включает от 0,01 до 10 мг соединения формулы I (эквивалент свободного основания) или соединения формулы II (эквивалент свободного основания) или соединения формулы III (эквивалент свободного основания).
6. Композиция по любому из предшествующих пунктов, дополнительно включающая один или несколько гидрофильных водорастворимых или набухающих в воде полимеров.
7. Композиция по п. 6, где полимер выбран из группы, состоящей из природных или модифицированных целлюлозных полимеров, полимеров этиленоксида и/или пропиленоксида, полимеров, включающих мономеры акриловой кислоты, природных или модифицированных смол (например, ксантановой камеди), природных или модифицированных крахмалов (например, предварительно желатинизированных крахмалов) или любой их смеси.
8. Композиция по любому из предшествующих пунктов, дополнительно включающая один или несколько эксципиентов, выбранных из группы, состоящей из пластификаторов, поверхностно-активных веществ, осушителей, ароматизаторов, подсластителей, связующих, разрыхлителей, увлажнителей (например, полиолов), смачивающих агентов, антиоксидантов, буферных агентов (например, кислот, оснований и/или их солей) и загустителей (например, гелеобразующих агентов).
9. Композиция по любому из предшествующих пунктов, где композиция представляет собой быстрорастворимую таблетку или облатку, например сублингвальную таблетку или облатку.
10. Композиция по любому из пп. 1-8, где композиция представляет собой пероральный спрей, например сублингвальный спрей или буккальный спрей.
11. Композиция по любому из пп. 1-8, где композиция представляет собой быстрорастворимую пленку, например сублингвальную пленку или буккальную пленку.
12. Композиция по п. 11, где пленка имеет однородную или по существу однородную толщину.
13. Композиция по п. 11 или 12, где соединение формулы I или II или III равномерно или по существу равномерно распределено по всей пленке.
14. Композиция по любому из пп. 1-8, где композиция представляет собой интраназальный спрей.
15. Композиция по любому из пп. 1-8, где композиция представляет собой пероральный гель, например быстрорастворимый сублингвальный или буккальный гель.
16. Композиция по любому из пп. 1-8, где композиция представляет собой интравагинальную композицию, например интравагинальную быстрорастворимую таблетку, облатку или гель, или интравагинальный спрей, или интравагинальную быстрорастворимую пленку.
17. Композиция по любому из предшествующих пунктов, где соединение формулы I, или соединение формулы II, или соединение формулы III включено в композицию в виде микрочастиц (например, частиц, имеющих средний диаметр менее 50 мкм, менее 30 мкм, менее 10 мкм или менее 5 мкм, или менее 1 мкм).
18. Композиция по любому из предшествующих пунктов, где соединение формулы I, или соединение формулы II, или соединение формулы III включено в композицию в виде микрочастиц (например, частиц, имеющих средний диаметр менее 100 нм, менее 50 нм или менее 10 нм).
19. Композиция по любому из предшествующих пунктов, где композиция абсорбируется слизистой оболочкой (например, растворяется) менее чем через 30 секунд после введения.
20. Подкожная фармацевтическая композиция, включающая 1-(4-фтор-фенил)-4-((6bR,10aS)-3-метил-2,3,6b,9,10,10a-гексагидро-1H,7H-пиридо[3′,4′:4,5]пирроло[1,2,3-de]хиноксалин-8-ил)-бутан-1-он (Соединение формулы I) в форме свободного основания, со-кристалла или соли, или включающая 1-(4-фтор-фенил)-4-((6bR,10aS)-2,2-d2-3-метил-2,3,6b,9,10,10a-гексагидро-1H,7H-пиридо[3′,4′:4,5]пирроло[1,2,3-de]хиноксалин-8-ил)-бутан-1-он (Соединение формулы II) в форме свободного основания, со-кристалла или соли, или включающая 1-(4-фтор-фенил)-4-((6bR,10aS)-1,1,2,2-d4-3-метил-2,3,6b,9,10,10a-гексагидро-1H,7H-пиридо[3′,4′:4,5]пирроло[1,2,3-de]хиноксалин-8-ил)-бутан-1-он (Соединение формулы III) в форме свободного основания, со-кристалла или соли.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762476538P | 2017-03-24 | 2017-03-24 | |
| US62/476,538 | 2017-03-24 | ||
| PCT/US2018/024150 WO2018175969A1 (en) | 2017-03-24 | 2018-03-23 | Novel compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2022103663A Division RU2022103663A (ru) | 2017-03-24 | 2018-03-23 | Новые композиции и способы |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019133676A true RU2019133676A (ru) | 2021-04-26 |
| RU2019133676A3 RU2019133676A3 (ru) | 2021-07-19 |
| RU2767410C2 RU2767410C2 (ru) | 2022-03-17 |
Family
ID=63581397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019133676A RU2767410C2 (ru) | 2017-03-24 | 2018-03-23 | Новые композиции и способы |
| RU2022103663A RU2022103663A (ru) | 2017-03-24 | 2018-03-23 | Новые композиции и способы |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2022103663A RU2022103663A (ru) | 2017-03-24 | 2018-03-23 | Новые композиции и способы |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US10716786B2 (ru) |
| EP (1) | EP3600325A4 (ru) |
| JP (2) | JP7132939B2 (ru) |
| KR (2) | KR102398194B1 (ru) |
| CN (2) | CN110430879B (ru) |
| AU (2) | AU2018240540B2 (ru) |
| BR (1) | BR112019019875A2 (ru) |
| CA (1) | CA3054841A1 (ru) |
| IL (2) | IL268970B2 (ru) |
| MX (3) | MX2021013640A (ru) |
| RU (2) | RU2767410C2 (ru) |
| WO (1) | WO2018175969A1 (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013155504A1 (en) | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| MX2016007219A (es) * | 2013-12-03 | 2016-09-16 | Intra-Cellular Therapies Inc | Metodos novedosos. |
| US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN113786407A (zh) | 2016-01-26 | 2021-12-14 | 细胞内治疗公司 | 有机化合物 |
| KR20230003461A (ko) | 2016-03-25 | 2023-01-05 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| US11014925B2 (en) * | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| ES2901375T3 (es) | 2016-08-09 | 2022-03-22 | Teva Pharmaceuticals Int Gmbh | Formas en estado sólido de sal de ditosilato de lumateperona |
| MX2021013640A (es) | 2017-03-24 | 2022-08-31 | Intra Cellular Therapies Inc | Composiciones novedosas y metodos. |
| BR112020001654A2 (pt) | 2017-07-26 | 2020-07-21 | Intra-Cellular Therapies, Inc. | compostos orgânicos |
| JP2020535231A (ja) | 2017-09-26 | 2020-12-03 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規な塩および結晶 |
| US20210315891A1 (en) * | 2018-08-29 | 2021-10-14 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| CN112584837A (zh) * | 2018-08-31 | 2021-03-30 | 细胞内治疗公司 | 新方法 |
| US11753419B2 (en) | 2019-12-11 | 2023-09-12 | Intra-Cellular Therapies, Inc. | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
| MX2023004102A (es) * | 2020-10-09 | 2023-04-27 | Shujing Biopharma Co Ltd | Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo. |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
| US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
| US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
| US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
| US4136145A (en) | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| EP0283474A1 (de) | 1985-10-09 | 1988-09-28 | Desitin Arzneimittel GmbH | Verfahren zur herstellung einer darreichungs- und dosierungsform für arzneimittelwirkstoffe, reagentien oder andere wirkstoffe |
| ES2058068T3 (es) | 1986-03-19 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazol-(3,2-a)-pirimidin-5-ona y compuestos fungicidas con contenido en dichos derivados. |
| ES2058069T3 (es) | 1986-04-07 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado. |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| DE4018247A1 (de) | 1990-06-07 | 1991-12-12 | Lohmann Therapie Syst Lts | Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen |
| IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| ES2236700T3 (es) | 1993-11-19 | 2005-07-16 | Janssen Pharmaceutica N.V. | 1,2-benzazoles microencapsulados. |
| CZ284633B6 (cs) | 1994-03-02 | 1999-01-13 | Akzo Nobel N. V. | Farmaceutický prostředek a použití trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolu pro výrobu farmaceutického prostředku |
| DE69535592T2 (de) | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
| US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
| US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
| US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
| US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
| DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
| US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
| GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
| US6884429B2 (en) | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
| WO1999018057A1 (en) | 1997-10-06 | 1999-04-15 | Massachusetts Institute Of Technology | Preparation of diaryl ether by condensation reactions |
| US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
| ATE229499T1 (de) | 1998-02-26 | 2002-12-15 | Massachusetts Inst Technology | Metallkatalysierte arylierungen und vinylierungen von hydrazinen, hydrazonen, hydroxylaminen und oximen |
| US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
| US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| ATE316532T1 (de) | 1998-07-10 | 2006-02-15 | Massachusetts Inst Technology | Liganden für metalle und metall-katalysiertes verfahren |
| US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| PT1140012E (pt) | 1998-12-17 | 2004-05-31 | Alza Corp | Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| NO309305B1 (no) | 1999-02-19 | 2001-01-15 | Norsk Hydro As | Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater |
| US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
| AR023574A1 (es) | 1999-04-23 | 2002-09-04 | Pharmacia & Upjohn Co Llc | Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios |
| US6713471B1 (en) * | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| IL145998A0 (en) | 1999-06-15 | 2002-07-25 | Du Pont Pharm Co | Substituted heterocycle fused gamma-carbolines |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| DK1104760T3 (da) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
| JP2004509894A (ja) | 2000-09-20 | 2004-04-02 | ファルマシア・アンド・アップジョン・カンパニー | 置換アゼピノ［４，５−ｂ］インドリン誘導体 |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| EP1343791A2 (en) | 2000-12-20 | 2003-09-17 | Bristol-Myers Squibb Company | Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists |
| CA2445159C (en) | 2001-04-24 | 2012-09-11 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| DE10123129A1 (de) | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel |
| ATE444060T1 (de) | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
| WO2003014118A1 (en) | 2001-08-08 | 2003-02-20 | Pharmacia & Upjohn Company | THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| EP1314554A1 (fr) | 2001-11-23 | 2003-05-28 | Kba-Giori S.A. | Dispositif de décollage d'éléments de sécurité |
| DE10162121A1 (de) | 2001-12-12 | 2003-06-18 | Berolina Drug Dev Ab Svedala | Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel |
| ATE373472T1 (de) | 2002-07-29 | 2007-10-15 | Alza Corp | Verfahren und dosierformen für die kontrollierte abgabe von paliperidon |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| EP1534671A4 (en) | 2002-08-02 | 2007-10-24 | Massachusetts Inst Technology | FORMATION OF CARBON-HETEROATOME AND CARBON-CARBON BONDS CATALYZED WITH COPPER |
| AU2003287433A1 (en) | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| AU2003303210A1 (en) | 2002-12-19 | 2004-07-14 | Bristol-Myers Squibb Company | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
| CN1816524B (zh) | 2003-01-16 | 2012-06-27 | 阿卡蒂亚药品公司 | 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂 |
| RU2006106429A (ru) | 2003-07-21 | 2006-08-27 | СмитКлайн Бичем Корпорейшн (US) | Соль (2s, 4s)-4-фтор-1-(4-фтор-бета-(4-фторфенил)-l-фенилаланил) -2-пирролидинкарбонитрила с пара-толуолсульфоновой кислоты и ее безводные кристаллические формы |
| AR045796A1 (es) | 2003-09-26 | 2005-11-16 | Solvay Pharm Bv | Derivados de hexa y octahidro - pirido (1,2-a) pirazina con actividad antagonista de nk1. composiciones farmaceuticas. |
| JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
| EP1756102A1 (en) | 2004-03-05 | 2007-02-28 | Pharma C S.A. | 8-PHENOXY-GammaCARBOLINE DERIVATIVES |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| WO2006034187A2 (en) | 2004-09-20 | 2006-03-30 | Mount Sinai School Of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| MX2007002459A (es) | 2004-09-21 | 2007-05-04 | Pfizer Prod Inc | N-metilhidroxietilamina util en el tratamiento de afecciones del snc. |
| US7614727B2 (en) | 2004-09-30 | 2009-11-10 | Fujifilm Corporation | Liquid ejection head, manufacturing method thereof, and image forming apparatus |
| ATE457989T1 (de) | 2004-12-15 | 2010-03-15 | Hoffmann La Roche | Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit |
| WO2006081251A2 (en) | 2005-01-25 | 2006-08-03 | Celgene Corporation | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione |
| KR20070097590A (ko) | 2005-01-25 | 2007-10-04 | 에픽스 델라웨어, 인코포레이티드 | 치환된 아릴아민 화합물 및 5―ｈｔ6 조절제로서의 이의용도 |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| JP2009507071A (ja) | 2005-09-07 | 2009-02-19 | ビバース、インコーポレイテッド | ビタミンｂ１２組成物 |
| CA2624179A1 (en) | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| RU2008127501A (ru) | 2006-01-13 | 2010-02-20 | Вайет (Us) | Сульфонилзамещенные 1н-индолы в качастве лигандов 5-гидрокситриптаминовых рецепторов |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
| JP5567349B2 (ja) | 2007-03-12 | 2014-08-06 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ−カルボリンの合成 |
| JP5754885B2 (ja) | 2007-06-21 | 2015-07-29 | 株式会社フジモト・コーポレーション | 経皮または経粘膜投与用組成物 |
| AU2008282742A1 (en) | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| EP2180844B1 (en) | 2007-08-02 | 2018-02-21 | Insys Development Company, Inc. | Sublingual fentanyl spray |
| WO2009023253A2 (en) | 2007-08-15 | 2009-02-19 | Arena Pharmaceuticals Inc. | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
| US20090209608A1 (en) | 2007-08-29 | 2009-08-20 | Protia, Llc | Deuterium-enriched asenapine |
| US20090076159A1 (en) | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched eplivanserin |
| AU2009212065B2 (en) | 2008-02-05 | 2014-03-20 | Clera Inc. | Compositions and methods for alleviating depression or improving cognition |
| CA2713935C (en) | 2008-02-07 | 2016-11-01 | Schering Corporation | Engineered anti-tslpr antibodies |
| KR20150140418A (ko) | 2008-03-12 | 2015-12-15 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로사이클 융합 감마-카볼라인 고체 |
| MX2010013020A (es) | 2008-05-27 | 2011-03-21 | Intra Cellular Therapies Inc | Metodos y composiciones para trastornos del sueño y otros trastornos. |
| US8309772B2 (en) | 2008-07-31 | 2012-11-13 | Celanese International Corporation | Tunable catalyst gas phase hydrogenation of carboxylic acids |
| US20100159033A1 (en) | 2008-09-29 | 2010-06-24 | Auspex Pharmaceuticals, Inc. | Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor |
| WO2011044019A1 (en) | 2009-10-05 | 2011-04-14 | Bristol-Myers Squibb Company | (R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES |
| EP2560676B8 (en) | 2010-04-22 | 2016-10-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| NZ612686A (en) | 2010-12-16 | 2015-11-27 | Cynapsus Therapeutics Inc | Sublingual films |
| WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
| US20150004237A1 (en) | 2012-01-09 | 2015-01-01 | Virginia Tech Intellectual Properties, Inc. | Cellulose derivatives for inhibiting crystallization of poorly water-soluble drugs |
| WO2013155504A1 (en) | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP2014074145A (ja) | 2012-10-05 | 2014-04-24 | Olympus Corp | セルロースナノファイバーとその製造方法、複合樹脂組成物、成形体 |
| WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| US9708322B2 (en) | 2013-03-15 | 2017-07-18 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity |
| ES2802976T3 (es) | 2013-09-10 | 2021-01-22 | Fresh Cut Dev Llc | Pulverizador de buprenorfina sublingual |
| CN105579029B (zh) | 2013-09-30 | 2019-03-05 | 硕腾服务有限责任公司 | 长效螺异恶唑啉制剂 |
| MX2016007219A (es) | 2013-12-03 | 2016-09-16 | Intra-Cellular Therapies Inc | Metodos novedosos. |
| US9745300B2 (en) | 2014-04-04 | 2017-08-29 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| AU2016272089B2 (en) * | 2015-06-03 | 2021-02-18 | Triastek, Inc. | Dosage forms and use thereof |
| WO2017117514A1 (en) | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| CN113786407A (zh) | 2016-01-26 | 2021-12-14 | 细胞内治疗公司 | 有机化合物 |
| WO2017165755A1 (en) | 2016-03-25 | 2017-09-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20230003461A (ko) | 2016-03-25 | 2023-01-05 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| WO2017172784A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| ES2901375T3 (es) | 2016-08-09 | 2022-03-22 | Teva Pharmaceuticals Int Gmbh | Formas en estado sólido de sal de ditosilato de lumateperona |
| JP7013454B2 (ja) | 2016-10-12 | 2022-02-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
| WO2018106916A1 (en) | 2016-12-07 | 2018-06-14 | Concert Pharmaceuticals, Inc. | Deuterated quinoxaline compounds |
| MX2021013640A (es) * | 2017-03-24 | 2022-08-31 | Intra Cellular Therapies Inc | Composiciones novedosas y metodos. |
| WO2018189646A1 (en) | 2017-04-10 | 2018-10-18 | Dr. Reddy's Laboratories Limited | AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE |
| BR112020001654A2 (pt) | 2017-07-26 | 2020-07-21 | Intra-Cellular Therapies, Inc. | compostos orgânicos |
| IL272249B2 (en) | 2017-07-26 | 2023-11-01 | Intra Cellular Therapies Inc | organic compounds |
| WO2019102240A1 (en) | 2017-11-27 | 2019-05-31 | Egis Gyógyszergyár Zrt. | Method for the manufacture of lumateperone and its salts |
-
2018
- 2018-03-23 MX MX2021013640A patent/MX2021013640A/es unknown
- 2018-03-23 IL IL268970A patent/IL268970B2/en unknown
- 2018-03-23 MX MX2019011329A patent/MX2019011329A/es unknown
- 2018-03-23 KR KR1020197031454A patent/KR102398194B1/ko active IP Right Grant
- 2018-03-23 US US15/934,860 patent/US10716786B2/en active Active
- 2018-03-23 RU RU2019133676A patent/RU2767410C2/ru active
- 2018-03-23 BR BR112019019875A patent/BR112019019875A2/pt not_active Application Discontinuation
- 2018-03-23 CA CA3054841A patent/CA3054841A1/en active Pending
- 2018-03-23 AU AU2018240540A patent/AU2018240540B2/en active Active
- 2018-03-23 WO PCT/US2018/024150 patent/WO2018175969A1/en active Application Filing
- 2018-03-23 JP JP2019552023A patent/JP7132939B2/ja active Active
- 2018-03-23 CN CN201880018346.0A patent/CN110430879B/zh active Active
- 2018-03-23 CN CN202310342092.0A patent/CN116327770A/zh active Pending
- 2018-03-23 EP EP18771645.1A patent/EP3600325A4/en active Pending
- 2018-03-23 KR KR1020227015716A patent/KR20220066988A/ko not_active Application Discontinuation
- 2018-03-23 IL IL304026A patent/IL304026A/en unknown
- 2018-03-23 RU RU2022103663A patent/RU2022103663A/ru unknown
-
2019
- 2019-09-23 MX MX2022010797A patent/MX2022010797A/es unknown
-
2020
- 2020-06-12 US US16/900,746 patent/US11052083B2/en active Active
-
2021
- 2021-06-03 US US17/338,573 patent/US11806347B2/en active Active
- 2021-12-17 AU AU2021286423A patent/AU2021286423B2/en active Active
-
2022
- 2022-02-28 JP JP2022030100A patent/JP2022084651A/ja active Pending
-
2023
- 2023-05-17 US US18/319,425 patent/US20230301995A1/en active Pending
- 2023-09-27 US US18/476,138 patent/US20240016802A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019133676A (ru) | Новые композиции и способы | |
| JP2020512328A5 (ru) | ||
| US10238612B2 (en) | Transdermal administration of tamsulosin | |
| US5900247A (en) | Mucoadhesive pharmaceutical composition for the controlled release of active principles | |
| DK2968121T3 (en) | SUBLINGUAL AND BUCHAL FILM COMPOSITIONS | |
| RU2008137032A (ru) | Распадающиеся пероральные пленки | |
| US9597287B2 (en) | Edible oral strip or wafer dosage form containing ion exchange resin for taste masking | |
| JP2005526043A5 (ru) | ||
| US9937122B2 (en) | Palonosetron oral transmucosal film or patch | |
| JP2008533007A5 (ru) | ||
| BRPI0709382A2 (pt) | forma de dosagem sólida contendo um agente ativo de sabor mascarado | |
| RU2011136636A (ru) | Фармацевтическая композиция для орального введения | |
| JP2013515782A (ja) | オンダンセトロンを含む経口投与可能なフィルム製剤 | |
| WO2020086673A1 (en) | Ketamine oral transmucosal delivery system | |
| JP2016515523A5 (ru) | ||
| JP2019084352A5 (ru) | ||
| JP2018039810A5 (ru) | ||
| JP5421063B2 (ja) | ジクロフェナクナトリウム含有水性貼付剤 | |
| RU2007143087A (ru) | Композиция с модифицированным высвобождением минимум одной формы венлафаксина | |
| JP2010506855A5 (ru) | ||
| JPWO2020006092A5 (ru) | ||
| CN104940173A (zh) | 可溶性芬太尼及其衍生物口颊膜制剂及其制备方法 | |
| KR102153894B1 (ko) | 온단세트론 또는 이의 염을 함유하는 구강 붕해형 필름 제제 및 이의 제조방법 | |
| JP2016540748A (ja) | オンダンセトロン舌下スプレー製剤 | |
| KR20150117497A (ko) | 테노포비르디소프록실푸마레이트 필름형 제제 및 그 제조방법 |